Compare GSK plc (GSK) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Financial Select Sector SPDR Fund — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Financial Select Sector SPDR Fund trades at $54.76 (market cap $50.06B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| GSK | XLF | |
|---|---|---|
Market Cap | $91.88B | $50.06B |
Volume | 7,730,529 | 47,464,120 |
Sector | Health | — |
52-Week High | $61.18 | $58.55 |
52-Week Low | $43.24 | $47.80 |
Typical Hold Time | 93 Days | 104 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
XLF trades at $54.73, up 1.82% with a bearish technical signal as moving averages and ADX indicators suggest selling pressure. The financial ETF faces sector headwinds with bank stocks lagging the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
Financial sector exposure benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. The ETF's concentrated 76-holding portfolio offers targeted financial exposure while competing with broader alternatives. Sector rotation into financials by fund managers in Q2 2026 suggests institutional confidence despite recent relative weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
